Compare ALLR & PLSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALLR | PLSM |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | Israel |
| Employees | N/A | 63 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.3M | 22.0M |
| IPO Year | 2021 | N/A |
| Metric | ALLR | PLSM |
|---|---|---|
| Price | $1.73 | $4.49 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $9.75 | N/A |
| AVG Volume (30 Days) | ★ 212.0K | 31.9K |
| Earning Date | 05-15-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $320,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.77 | $3.00 |
| 52 Week High | $2.35 | $7.15 |
| Indicator | ALLR | PLSM |
|---|---|---|
| Relative Strength Index (RSI) | 67.92 | 57.25 |
| Support Level | $0.92 | $3.35 |
| Resistance Level | $1.79 | $5.00 |
| Average True Range (ATR) | 0.17 | 0.67 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 93.98 | 30.73 |
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.
Pulsenmore Ltd is an emerging medical device company engaged in the research, development, manufacturing, marketing, and sale of non-invasive portable ultrasound solutions for home use. Its products include the Pulsenmore ES and Pulsenmore FC, along with the early-stage Pulsenmore MC, collectively referred to as Pulsenmore Products, enabling remote ultrasound scans in gynecology and other fields such as pulmonary, cardiology, and urology through telemedicine. The Company operates in a single segment focused on developing and commercializing portable ultrasound technologies, with Israel contributing the majority of its revenue.